Skip to main content

Main menu

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC

User menu

Search

  • Advanced search
JPN
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC
JPN

Advanced Search

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow JPN on Twitter
Psychopharmacology for the Clinician

Acute renal and neurotoxicity in older lithium users: How can we manage and prevent these events in patients with late-life mood disorders?

Vincent Laliberté, Ching Yu and Soham Rej
J Psychiatry Neurosci July 01, 2015 40 (4) E29-E30; DOI: https://doi.org/10.1503/jpn.140359
Vincent Laliberté
From the Department of Psychiatry, McGill University, Montreal, QC., (Laliberté, Yu); and the Department of Psychiatry, University of Toronto, Toronto, Ontario (Rej).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ching Yu
From the Department of Psychiatry, McGill University, Montreal, QC., (Laliberté, Yu); and the Department of Psychiatry, University of Toronto, Toronto, Ontario (Rej).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soham Rej
From the Department of Psychiatry, McGill University, Montreal, QC., (Laliberté, Yu); and the Department of Psychiatry, University of Toronto, Toronto, Ontario (Rej).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

A 72-year-old man with a longstanding history of bipolar affective disorder type 1 had been stable on lithium monotherapy of 900 mg/night at a serum level of 0.8 mmol/L for more than 20 years. His family physician started him on hydrochlorothiazide (12.5 mg/d) for hypertension. One week later, the patient’s wife noticed unsteady gait, slurred speech and somnolence. The patient was brought to the emergency department, where he was found to have a lithium level of 1.7 mmol/L, a sodium level of 147 mmol/L, and an estimated glomerular filtration rate (eGFR) of 25 mL/min/1.73 m2. While admitted to hospital for an acute kidney injury (AKI), the patient was switched to valproate. The AKI and neurologic sequelae resolved with hydration, and his renal function returned to his baseline 65 mL/min/1.73 m2 within a year. In the years that followed, the patient was continued on valproate, but he experienced several depressive and hypomanic relapses.

Lithium toxicity is common in older users, with an annual incidence of 1.5% per year.1 Severe toxicity primarily manifests with neurologic sequelae (coarse tremor, gait difficulties, delirium, seizures, somnolence) and sometimes cardiac dysrhythmias.2 In addition, AKI and acute renal toxicity occur in 1.3%–4% of older lithium users over 5-year follow-up.3 These acute neurologic and renal manifestations generally resolve completely within 9–12 months,2,4 although sometimes renal impairment may be sustained.3

Toxicity symptoms are common at levels higher than 1.5 mEq/L, although chronic lithium intoxication at levels above 0.8mEq/L may also be dangerous in older adults.4 Natural aging also increases the risk for toxicity; the lithium dose required to achieve a given therapeutic serum level may decrease three-fold between the ages of 40 and 95 years, largely owing to decreased eGFR.5 Consequently, lithium and renal function need monitoring every 3 months with aging.4,5 Nephrogenic diabetes insipidus also increases toxicity risk, possibly through a feedback loop of elevated lithium levels causing acute diabetes insipidus and leading to further diuresis and lithium level elevations.6 Other risk factors include medications commonly prescribed in late life, such as diuretics, loop diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and nonsteroid anti-inflammatory drugs, which can increase lithium levels up to 50%.1

Despite the relatively low 0.5%–2% risk of serious long-term sequelae of lithium use,7 acute toxicity frequently leads to lithium discontinuation and rates of mood disorder relapse of 33%–50%.5,8 The potential for acute toxicity has led many clinicians to avoid prescribing lithium for older adults and choose agents, such as valproate,9 even though cognitive dysfunction and dementia rates may be worse with valproate.10 Whether lithium increases the long-term risk of chronic kidney disease11 remains unclear. It is true that 0.5%–2% of patients may eventually require chronic dialysis and that continued lithium exposure can be associated with accelerated renal decline in older adults with premorbid eGFR lower than 60 mL/min/1.73 m2.12 However, renal decline does not appear to exceed normal aging in most older adults treated with lithium levels below 0.8 mmol/L, particularly at levels below 0.5 mmol/L.13 Aging, diabetes, hypertension and heart disease14 account for most renal dysfunction seen in patients with mood disorders.15

In this clinical vignette, the recent initiation of hydrochlorothiazide likely led to a cascade of events: increased lithium level, acute nephrogenic diabetes insipidus, dehydration, AKI and reduced renal clearance, leading to further lithium level increases.6 In this case, permanent renal4 and neurologic damage are unlikely.2 The patient also had a history of poor psychiatric course following lithium discontinuation. Considering that 30%–40% of patients with bipolar disorder are preferential lithium responders16 and that lithium can potentially prevent suicide, a retrial of lithium may be beneficial in our patient’s case especially because lithium responders often do not respond to other treatments. Careful titration of lithium, caution about drug interactions (e.g., diuretics), and regular lithium and renal (eGFR) monitoring can help prevent further toxicity episodes in older adults.6

Footnotes

  • The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in this column is a composite with characteristics of several real patients.

  • Competing interests: None delcared.

References

  1. ↵
    1. Juurlink DN,
    2. Mamdani MM,
    3. Kopp A,
    4. et al
    .Drug-induced lithium toxicity in the elderly: a population-based study.J Am Geriatr Soc 2004;52:794–8.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Chen KP,
    2. Shen WW,
    3. Lu ML
    .Implication of serum concentration monitoring in patients with lithium intoxication.Psychiatry Clin Neurosci 2004;58:25–9.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rej S,
    2. Shulman K,
    3. Herrmann N,
    4. et al
    .Prevalence and correlates of renal disease in older lithium users: a population-based study.Am J Geriatr Psychiatry 2014;22:1075–82.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kirkham E,
    2. Skinner J,
    3. Anderson T,
    4. et al
    .One lithium level >1.0 mmol/L causes an acute decline in eGFR: findings from a retrospective analysis of a monitoring database.BMJ Open 2014;4:e006020
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Rej S,
    2. Beaulieu S,
    3. Segal M,
    4. et al
    .Lithium dosing and serum concentrations across the age spectrum: from early adulthood to the tenth decade of life.Drugs Aging 2014;31:911–6.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Rej S,
    2. Elie D,
    3. Mucsi I,
    4. et al
    .Chronic kidney disease in lithium-treated older adults: a review of epidemiology, mechanisms, and implications for the treatment of late-life mood disorders.Drugs Aging 2015;32:31–42.
    OpenUrl
  7. ↵
    1. Bendz H,
    2. Schon S,
    3. Attman PO,
    4. et al
    .Renal failure occurs in chronic lithium treatment but is uncommon.Kidney Int 2010;77:219–24.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Fahy S,
    2. Lawlor BA
    .Discontinuation of lithium augmentation in an elderly cohort.Int J Geriatr Psychiatry 2001;16:1004–9.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Shulman KI,
    2. Rochon P,
    3. Sykora K,
    4. et al
    .Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence.BMJ 2003;326:960–1.
    OpenUrlFREE Full Text
  10. ↵
    1. Kessing LV,
    2. Sondergard L,
    3. Forman JL,
    4. et al
    .Lithium treatment and risk of dementia.Arch Gen Psychiatry 2008;65:1331–5.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bocchetta A,
    2. Ardau R,
    3. Carta P,
    4. et al
    .Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study.BMC Med 2013;11:33
    OpenUrlCrossRefPubMed
  12. ↵
    1. Rej S,
    2. Abitbol R,
    3. Looper K,
    4. et al
    .Chronic renal failure in lithium-using geriatric patients: effects of lithium continuation versus discontinuation–a 60-month retrospective study.Int J Geriatr Psychiatry 2013;28:450–3.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Aprahamian I,
    2. Santos FS,
    3. dos Santos B,
    4. et al
    .Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension.J Clin Psychiatry 2014;75:e672–8.
    OpenUrl
  14. ↵
    1. Coresh J,
    2. Selvin E,
    3. Stevens LA,
    4. et al
    .Prevalence of chronic kidney disease in the United States.JAMA 2007;298:2038–47.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Forty L,
    2. Ulanova A,
    3. Jones L,
    4. et al
    .Comorbid medical illness in bipolar disorder.Br J Psychiatry 2014;205:465–72.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Grof P,
    2. Duffy A,
    3. Cavazzoni P,
    4. et al
    .Is response to prophylactic lithium a familial trait?.J Clin Psychiatry 2002;63:942–7.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of Psychiatry and Neuroscience: 40 (4)
J Psychiatry Neurosci
Vol. 40, Issue 4
1 Jul 2015
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on JPN.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Acute renal and neurotoxicity in older lithium users: How can we manage and prevent these events in patients with late-life mood disorders?
(Your Name) has sent you a message from JPN
(Your Name) thought you would like to see the JPN web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Acute renal and neurotoxicity in older lithium users: How can we manage and prevent these events in patients with late-life mood disorders?
Vincent Laliberté, Ching Yu, Soham Rej
J Psychiatry Neurosci Jul 2015, 40 (4) E29-E30; DOI: 10.1503/jpn.140359

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Acute renal and neurotoxicity in older lithium users: How can we manage and prevent these events in patients with late-life mood disorders?
Vincent Laliberté, Ching Yu, Soham Rej
J Psychiatry Neurosci Jul 2015, 40 (4) E29-E30; DOI: 10.1503/jpn.140359
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Alerts
  • RSS

Authors & Reviewers

  • Overview for Authors
  • Submit a manuscript
  • Manuscript Submission Checklist

About

  • General Information
  • Staff
  • Editorial Board
  • Contact Us
  • Advertising
  • Reprints
  • Copyright and Permissions
  • Accessibility
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1180-4882.

All editorial matter in JPN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.
To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].
View CMA's Accessibility policy.

Powered by HighWire